Lonafarnib

Drug Profile

Lonafarnib

Alternative Names: EBP 994; MK-6336; Sarasar; SCH 066336; SCH 66336

Latest Information Update: 29 May 2017

Price : $50

At a glance

  • Originator Schering-Plough
  • Developer Childrens Hospital Boston; Duke University; Eiger BioPharmaceuticals, Inc.; Merck & Co; National Institute of Diabetes and Digestive and Kidney Diseases; Schering-Plough; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Farnesyltranstransferase inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatitis D
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis D
  • Discontinued Breast cancer; Chronic myelomonocytic leukaemia; Glioblastoma; Glioma; Head and neck cancer; Leukaemia; Myelodysplastic syndromes; Non-small cell lung cancer; Pancreatic cancer; Progeria; Solid tumours

Most Recent Events

  • 21 Apr 2017 Pooled efficacy data from the phase II LOWR HDV programme in Hepatitis D presented at the The International Liver Congress (ILC-2017)
  • 15 Nov 2016 Updated efficacy and adverse events data from the phase II LOWR HDV-4 trial in Hepatitis D released by Eiger BioPharmaceuticals
  • 14 Nov 2016 Efficacy and adverse events data from the phase II LOWR HDV-4 trial in Hepatitis D (Combination therapy) released by Eiger BioPharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top